glycine p-nitrophenyl ester | 69753-66-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: glycine p-nitrophenyl ester
• 英文别名: 2-nitrophenyl glycine；(2-Nitrophenyl) 2-aminoacetate
• CAS: 69753-66-8
• 化学式: C₈H₈N₂O₄
• 分子量: 196.163
• InChiKey: YSROVWBNPNRGKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  98.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  glycine p-nitrophenyl ester 、 在 N-甲基吗啉 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以58%的产率得到1-(o-nitrophenylthio)aminocyclopropane-1-carbonylglycine p-nitrophenyl ester
  参考文献：
  名称：

  Stewart, Frederick H. C., Australian Journal of Chemistry, 1981, vol. 34, # 11, p. 2431 - 2438

  摘要：

  DOI：

文献信息

• [EN] NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND USE THEREOF<br/>[FR] COMPOSÉS DE LIAISON D'ACIDE NUCLÉIQUE, PROCÉDÉS DE FABRICATION, ET UTILISATION DE CEUX-CI
  申请人：UNIV ROCHESTER

  公开号：WO2012092367A1

  公开（公告）日：2012-07-05

  The present invention relates to oligomer compounds, including dimers and trimers, formed by a disulfide, sulfinyl thio, olefin or hydrocarbon bond, or a hydrazone exchange bond between two or more monomers. Methods of making the monomers and the oligomers is also disclosed. Use of the compounds for inhibiting the activity of target RNA molecules, particularly those having a secondary structure that include a stem or stem-loop formation. Dimer compounds capable of inhibiting the activity of an HIV-1 RNA frameshifting stem-loop and a (CUG)n expanded repeat stem- loop are disclosed, as are methods of treating diseases associated with these target RNA molecules.

  本发明涉及由二硫化物、亚硫醚硫、烯烃或碳氢键，或两个或更多单体之间的缩醛交换键形成的寡聚物化合物，包括二聚体和三聚体。还公开了制备单体和寡聚物的方法。利用这些化合物抑制靶RNA分子的活性，特别是那些具有包括茎或茎环形成的二级结构的RNA分子的活性。公开了能够抑制HIV-1 RNA移码茎环和(CUG)n扩展重复茎环活性的二聚体化合物，以及治疗与这些靶RNA分子相关的疾病的方法。
• BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION
  申请人：Dore Timothy M.

  公开号：US20100048502A1

  公开（公告）日：2010-02-25

  The disclosure encompasses caged compounds such as caged nucleoside phosphoesters (caged nucleotides). In an embodiment, the caged nucleotides include compounds corresponding to those described by formula (I) that may be activated by two-photon excitation, and methods of synthesis of such compounds. 8-Bromo-7-hydroxyquinoline-caged ATP was synthesized and examined for its photochemistry as a biologically useful, temporally and spatially controlled ATP-releasing reagent. The combination of two-photon excitation hydrolysis and activation of caged ATP enables methods for finely focusing ATP activation at the sub-cellular level or to a greater depth of activation, thereby providing improved resolution of ATP-dependent processes at the cellular level.

  该披露涵盖了笼状化合物，例如笼状核苷酸磷酸酯（笼状核苷酸）。在一种实施方案中，笼状核苷酸包括与公式（I）描述的化合物相对应的化合物，可以通过双光子激发激活，并提供了这种化合物的合成方法。合成了8-溴-7-羟基喹啉笼状ATP，并对其光化学性质进行了检查，作为一种生物学上有用的、时间和空间可控的ATP释放试剂。双光子激发水解和笼状ATP的激活相结合，可以在亚细胞水平或更深的激活深度上精细地聚焦ATP的激活，从而提供了更好的细胞水平上ATP依赖过程的分辨率。
• NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND USE THEREOF
  申请人：Miller Benjamin L.

  公开号：US20140050778A1

  公开（公告）日：2014-02-20

  The present invention relates to oligomer compounds, including dimers and trimers, formed by a disulfide, sulfinyl thio, olefin or hydrocarbon bond, or a hydrazone exchange bond between two or more monomers. Methods of making the monomers and the oligomers is also disclosed. Use of the compounds for inhibiting the activity of target RNA molecules, particularly those having a secondary structure that include a stem or stem-loop formation. Dimer compounds capable of inhibiting the activity of an HIV-1 RNA frameshifting stem-loop and a (CUG)n expanded repeat stem-loop are disclosed, as are methods of treating diseases associated with these target RNA molecules.

  本发明涉及由二硫键、亚磺酰基硫、烯烃或碳氢键或者两个或多个单体之间的肼交换键形成的寡聚物化合物，包括二聚体和三聚体。本发明还公开了制备单体和寡聚物的方法。该化合物用于抑制目标RNA分子的活性，特别是那些具有包括茎或茎环形成的二级结构的RNA分子。公开了能够抑制HIV-1RNA框移茎环和（CUG）n扩展重复茎环的二聚体化合物，以及治疗与这些目标RNA分子相关的疾病的方法。
• (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0371564A2

  公开（公告）日：1990-06-06

  Novel (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives of formula the pharmaceutical acceptable acid addition salts thereof and the stereochemically isomeric forms thereof, wherein -X1 =X2- is -CH = CH-, -CH = N-, or -N = CH-; R is hydrogen or C1-6alkyl; Y is hydrogen, C1-10alkyl, C3-7cycloalkyl, Arl, Ar2-C1-6alkyl, C2-6alkenyl or C2-6alkynyl; Z is a radical of formula which compounds are useful for treating disorders which are characterized by an excessive proliferation and/or abnormal differentiation of epithelial tissues: pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.

  式中的新型(1H-唑-1-基甲基)取代的喹啉、喹唑啉或喹喔啉衍生物 其中 -X1 =X2- 是 -CH = CH-、-CH = N-或 -N = CH-；R 是氢或 C1-6 烷基；Y 是氢、C1-10 烷基、C3-7 环烷基、Arl、Ar2-C1-6 烷基、C2-6 烯基或 C2-6 烷炔基；Z 是式中的一个基团 这些化合物可用于治疗以上皮组织过度增殖和/或异常分化为特征的疾病：含有此类化合物作为活性成分的药物组合物，以及制备所述化合物和药物组合物的方法。
• Orthogonal translation components for the in vivo incorporation of unnatural amino acids
  申请人：The Scripps Research Institute

  公开号：EP2383340A2

  公开（公告）日：2011-11-02

  The invention relates to orthogonal pairs of tRNAs and aminoacyl-tRNA synthetases that can incorporate unnatural amino acids into proteins produced in eubacterial host cells such as E.coli, or in a eukaryotic host such as a yeast cell. The invention provides, for example but not limited to, novel orthogonal synthetases, methods for identifying and making the novel synthetases, methods for producing proteins containing unnatural amino acids, and translation systems.

  本发明涉及正交对 tRNA 和氨基酰-tRNA 合成酶，它们可以将非天然氨基酸掺入到在真细菌宿主细胞（如大肠杆菌）或真核细胞宿主（如酵母细胞）中生产的蛋白质中。本发明提供了例如但不限于新型正交合成酶、鉴定和制造新型合成酶的方法、生产含有非天然氨基酸的蛋白质的方法以及翻译系统。